Ovarian Cancer

In the phase 3 DUO-O study, combing 5 targeted and chemotherapy agents for the treatment of newly diagnosed, advanced, high-grade epithelial ovarian cancer with or without BRCA mutations has shown to extend progression-free survival.

Bruno Bockorny, MD, discusses the findings from a study of botensilimab plus bastilimab for the treatment of patients with recurrent platinum refractory/resistant ovarian cancer.

In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit. In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit.

Carolina Frailty Index Score can effectively assess frailty status in women with ovarian cancer.

Among patients with newly diagnosed, advanced ovarian cancer, dose modifications to frontline niraparib maintenance therapy did not affect progression-free survival.

The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and tremelimumab, combined with neoadjuvant chemotherapy for the treatment of patients with newly diagnosed advanced ovarian cancer.

John Diaz, MD, discusses some of the challenges with using targeted therapies in the ovarian cancer space.

According to Vadim Gushchin, MD, treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of how it may impact a patient’s health-related quality of life.

During a Targeted Oncology™ Case-Based Roundtable™ event, Paul D. DiSilvestro, MD, discussed the updated results of the PAOLA-1 trial of bevacizumab followed by olaparib maintenance in patients with advanced ovarian cancer. This is the third of 3 articles based on this event.

A new study investigation ART0380 and gemcitabine for the treatment of patients with platinum-resistant ovarian cancer has begun.

John Diaz, MD, discusses some of the targeted therapies that are showing promise for patients with ovarian cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Paul DiSilvestro, MD, discussed the results of the PRIMA trial of niraparib maintenance therapy for patients with advanced ovarian cancer. This is the second of 3 articles based on this event.

The UPGRADE-A trial assessing the combination of upifitamab rilsodotin and carboplatin in patients with platinum-sensitive high-grade serous ovarian cancer has initiated the dose-expansion portion of the study.

In an interview with Targeted Oncology, John Diaz, MD summarized the ovarian cancer treatment paradigm, and discussed the role of genomic testing and novel targets being explored in the space.

Based on findings from the phase 3 SORAYA trial, mirvetuximab soravtansine gained FDA approval for the treatment of patients with folate receptor alpha-high platinum-resistant ovarian cancer.

David O’Malley, MD, discusses the mechanism of action of ubamatamab as well as findings from a phase 1 trial evaluating the agent in patients with recurrent ovarian cancer.

With encouraging response rates and a well-tolerated safety profile seen in RAMP-201, experts are hopeful for the accelerated approval of avutometinib plus defactinib for low-grade serous ovarian cancer.

Susana Banerjee, MBBS, PhD, discusses the significance of the long-term results of the MEDIOLA trial of patients with ovarian cancer.

During a Targeted Oncology case-based roundtable event, Paul D. DiSilvestro, MD, discussed the long-term results from the SOLO-1 trial of olaparib maintenance for patients with ovarian cancer. This is the first of 3 articles based on this event.

Erika P. Hamilton, MD, discusses the findings from a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.

Based on the positive interim safety data from a phase 1 trial of STRO-002, the phase 2/3 REFRaME study will be initiated to further evaluate the agent in patients with advanced ovarian cancer.

Shannon N. Westin, MD and a group of peers discussed key consideration when approaching management of a patient with ovarian cancer.

Susana Banerjee, MBBS, PhD, discusses the updated results of the MEDIOLA trial of patients with ovarian cancer presented at the 2022 European Society for Medical Oncology Congress.

During a Targeted Oncology case-based roundtable event, Ritu Salani, MD, MBA, discussed multiple studies that back up the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer.

The new VENTANA FOLR1 RxDx Assay has been approved by the FDA and will aid in identifying patients with ovarian cancer who are eligible for targeted treatment with mirvetuximab soravtansine.